BIOVERATIV INC (BIVV) Stock News
NASDAQ:BIVV - Nasdaq -
BIVV Latest News, Press Relases and Analysis
Swiss Man Charged in $4.7 Million Sanofi Insider Scheme
A Swiss man was charged in the U.S. with illegally making more than $4.7 million in trading on an insider tip about Sanofi’s 2018 acquisition of Bioverativ, a developer of hemophilia therapies.
Spectrum Pharma Is Weighing a Sale
Spectrum Pharmaceuticals Inc., a U.S. biotech company focused on oncology and hematology, is exploring options including a sale of the business amid takeover interest from other drugmakers, people familiar with the matter said.
Lilly Is Spending $1.6 Billion To 'Leapfrog' Merck, Bristol — Will It Work?
Eli Lilly put up a $1.6 billion bid to buy cancer immunotherapy biotech Armo Biosciences early Thursday in a plan to bolster its immuno-oncology assets.
Allergan Bows Out Of Shire Battle Against Takeda After Stock Slammed
In a rapid turnaround, Allergan said late Thursday it doesn't intend to bid on Shire — leaving thrice-rebuffed Takeda Pharmaceuticals alone in the race for the rare disease drugmaker.
Allergan Reportedly Enters Fray To Buy Shire, Rivaling Takeda
Shire is reportedly in the middle of a bidding war after it rejected three proposals from Takeda and then received new interest from Allergan, according to reports early Thursday.
Bioverativ Inc. (BIVV): Earnings News
BIVV – Beats Wall Street consensus EPS estimates by $0.06 and beats on revenues.
These 12 Drugs Launching In 2018 Are Headed For Blockbuster Status
A dozen drugs launching in 2018 from heavy hitters like Roche, Gilead Sciences and Johnson & Johnson are expected to reach blockbuster status by the end of 2022, an analytics firm says. Clarivate Analytics describes 2018 as "the year of the blockbuster," in which these 12 drugs have either launched or are expected to launch, and eventually bring in north of $1 billion in sales over a five-year period. That's the biggest number since Clarivate began making its forecast in 2013. It's setting up "to be an exciting year that will see valuable additions to existing treatments as well as disruptions to certain markets and first-in-class treatment options for some diseases," the firm said in its report, issued late Thursday. By the end of 2022, three drugs from Roche, Gilead and Novo Nordisk are expected to top $3 billion each in annual sales with the remaining nine likely to account for $1 billion to $2 billion a year in revenue, analysts said. Among the 12 are two diabetes drugs, a
Bioverativ Inc. (BIVV): Neutral Rating Reiterated
BIVV – William Blair reiterates Hold rating. Stock price at the time of this analyst call was $104.65.
Bioverativ Inc Gets a Hold Rating from William Blair
William Blair analyst Raju Prasad maintained a Hold rating on Bioverativ Inc (NASDAQ: BIVV) today. The company’s shares opened today at $104.97, close to its 52-week high of $105.01. Prasad commented: “We are dropping coverage of Bioverativ , Inc. following the completion of its acquisition by Sanofi (SNY $39.90). Our final rating on Bioverativ was
The post Bioverativ Inc Gets a Hold Rating from William Blair appeared first on Analyst Ratings.
These Are The Top Stocks That Retail Investors Bought And Sold In A Wild February
Apple, Amazon, General Electric and Ford Motor ranked among top stock buys for retail investors last month even as the stock market entered a brief correction.
Investor Movement Index February Summary
The IMX posted the largest monthly decrease ever in February, as volatility returned to the market, decreasing over -23% to 5.95. The IMX was sharply lower during the February...
Bioverativ Announces First Patient Dosed in Phase 3 Study of BIVV009 for Treatment of Cold Agglutinin Disease
Biotech Crushing the Market: Best ETFs & Stocks YTD
Biotechnology sector, which includes the fast-growing companies in the health care world, are easily crushing the overall market and broader health care sector so far this year.
Biotechs: Still Well Placed For More Gains
The cold winds of February cut into the market as stocks found themselves going in an unaccustomed direction. Sliding like a toboggan, stocks last week experienced the sharpest correction in over 50 years, reaching the -10% mark within a week.
Bioverativ Inc. (BIVV): Hedge Fund News
BIVV – ValueAct Holdings (Jeffrey Ubben and Bradley Singer) discloses updated portfolio positions in 13F filing: Closed Position.
Bioverativ Reports Fourth Quarter and Full Year 2017 Performance
Earnings Scheduled For February 13, 2018
Companies Reporting Before The Bell Under Armour Inc (NYSE: UAA) is expected to report quarterly earnings at $0.01 per share on revenue of $1.31 billion. Diebold Nixdorf...
Here's How Sanofi Hopes to Avoid the Patent Cliff
Acquisitions may help the company navigate risks.
Mentions: SNY
Biotech M&A: Sanofi SA (ADR) Inks 2nd Multi-Billion Dollar Deal in a Week
Sanofi (SNY) inks second multi-dollar deal this month. Since the earlier deal last Monday, SNY stock gained 2.6% in a week.
Big Biotech Is Bustling With Buyouts
Merger mania returns to this notorious boom-or-bust industry.
Mentions: SNY
5 Biotech and Pharmaceutical Stocks Going Bonkers
These biotech and pharmaceutical stocks are soaring insanely high right now. Here's what investors should know about each of these hot stocks to buy.
The Law Offices of Vincent Wong Notifies Investors of an Investigation of Bioverativ Inc. in Connection with the Sale of the Company to Sanofi
Why Investors Should Stay Long Eli Lilly and Co Stock
LLY stock had a sudden drop on Jan. 22, but Eli Lilly and Co recovered the bulk of its losses, which means bulls can stay long for the time being.
WeissLaw LLP Investigates Bioverativ Inc. Acquisition
Bioverativ Inc. (BIVV): Neutral Rating Reiterated
BIVV – Argus Research reiterates Hold rating. Stock price at the time of this analyst call was $103.16.
Analysts Offer Insights on Healthcare Companies: Puma Biotechnology (NYSEArca: PBYI) and Bioverativ Inc (NASDAQ: BIVV)
Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Puma Biotechnology (NYSEArca: PBYI) and Bioverativ Inc (NASDAQ: BIVV). Puma Biotechnology (NYSEArca: PBYI) In a report released today, Yigal Nochomovitz from Citigroup maintained a Buy rating on Puma Biotechnology (NYSEArca: PBYI), with a price target of $146. The
The post Analysts Offer Insights on Healthcare Companies: Puma Biotechnology (NYSEArca: PBYI) and Bioverativ Inc (NASDAQ: BIVV) appeared first on Analyst Ratings.
Mentions: PBYI
2018 Could Be "The Year of M&A"
2017 was a good year, but not a great year, for global mergers and acquisition activity as global M&A fell just short of 2016 results with a 3.2% decline in value according to Mergermarket.
SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation of Bioverativ Inc. Buyout
Bioverativ Inc. (BIVV): Neutral Rating Reiterated
BIVV – Raymond James reiterates Market Perform rating. Stock price at the time of this analyst call was $103.79.
Bioverativ Inc. (BIVV): Upgrade News
BIVV – Morgan Stanley upgrades to Equal Weight from Underweight. Stock price at the time of this analyst call was $103.79.